Pharma Licensing, Partnering and Dealmaking Services
Licensing and partnering are the lifeblood of the biopharma industry and are vital elements of the growth strategy of pharma and biotech companies. We assist life sciences companies with their business and corporate development initiatives and activities. We provide a full range of dealmaking services to pharma, biotech and diagnostics companies seeking to internalize and externalize assets via inorganic strategy. We assist with both inbound deals and outbound deals and deal structuring.
Pharma In-licensing, Search, Evaluation and Due Diligence
For inbound deals:
We help you identify assets aligned with your strategy, evaluate scientific and clinical data, assess market size, investigate current competitive landscapes, analyze pipelines for future competitors, conduct KOL interviews, create forecasts, conduct NPV analysis and valuation, and help you with necessary due diligence in the VDR to close a value-creating deal. We assist with pre due diligence as well as due diligence during the dealmaking process.
Biotech Out-licensing, Partnering and Dealmaking Support
For outbound deals:
We help you find potential licensees, position your asset optimally, tell a compelling investment story to potential partners, reach out swiftly to a large number of partners and buyers, manage the data room/due diligence, assist you with valuation and offer selection, and help you close a value-maximizing deal. We work in sync with you as your extended team or we can run the licensing mandate independently- read our industry-leading guide on best practices for out-licensing and partnering pharma and biotech assets.
Deal Structuring
We assist clients with optimal deal structuring. If you are already in the deal-making process, then, we can support you with the terms sheet and structuring of the deal terms so that you receive or pay fair value. The key elements of such support are:
- Valuation of the opportunity and splitting the value pie
- Allocating value to various elements like upfront payments, milestones, and royalties
- Compounding and dissecting with add-on instruments like options, contingent value rights etc.
